Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 0.67 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.67 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GGT1 | P19440 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL29382620 | 1.00 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL26228 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL1939134 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL1457620 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL191054 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL4534925 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL7250097 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL21328428 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL162391 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL3677210 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-02-13 | — | — | US | claimed |
| US-9622969-B2 | Polymer conjugated protein micelles | SOUTH DAKOTA STATE UNIV (US) | 2017-04-18 | — | — | US | claimed |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | SOUTH DAKOTA STATE UNIVERSITY (US) | 2014-12-18 | — | — | US | claimed |
| US-20090312433-A1 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT | AMGEN INC. | 2009-12-17 | — | — | US | claimed |
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-1938803-A2 | Formulations comprising nanoparticulate meloxican | Elan Pharma International Limited (IE) | 2008-07-02 | — | — | EP | claimed |
| EP-1885348-A2 | ANTIPYRETIC AGENTS AGAINST VR1-ANTAGONIST-INDUCED INCREASES IN BODY TEMPERATURE | Amgen, Inc (US) | 2008-02-13 | — | — | EP | claimed |
| US-20060281718-A1 | Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent | AMGEN INC. | 2006-12-14 | — | — | US | claimed |
| EP-1480624-B1 | PHARMACEUTICAL TABLET | PHARMACIA CORP (US) | 2006-11-29 | — | — | EP | claimed |
| US-20040214753-A1 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | claimed |
| WO-2004082719-A1 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2004082588-A2 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040156872-A1 | Novel nimesulide compositions | ELAN PHARMA INTERNATIONAL LTD. | 2004-08-12 | — | — | US | claimed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| US-5731277-A | Automatic dishwashing compositions containing aluminum tetrahydroxide | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1998-03-24 | — | — | US | claimed |
| EP-0826024-A1 | AUTOMATIC DISHWASHING COMPOSITIONS CONTAINING ALUMINUM SALTS | UNILEVER N.V. (NL) | 1998-03-04 | — | — | EP | claimed |
| US-5698506-A | Automatic dishwashing compositions containing aluminum salts | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1997-12-16 | — | — | US | claimed |
| WO-1996036687-A1 | AUTOMATIC DISHWASHING COMPOSITIONS CONTAINING ALUMINUM SALTS | UNILEVER N.V. (NL) | 1996-11-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156872-A1 | Novel nimesulide compositions | NIM1K, NIT2, NCL | PTGS2 2387/4885PTGS1 1780/4885KDM4E 1888/4885 |
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | PTGS2 593/4885PTGS1 155/4885KDM4E 3204/4885 |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | GSTK1, GSTO1, GSTM2 | PTGS2 285/4885PTGS1 333/4885KDM4E 4520/4885 |
| US-20090312433-A1 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT | VRK1, VIPR1, AVPR1A | PTGS2 777/4885PTGS1 247/4885KDM4E 4666/4885 |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | MTDH, PSMG3, GHITM | PTGS2 2644/4885PTGS1 2339/4885KDM4E 3234/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | PTGS2 557/4885PTGS1 196/4885KDM4E 2862/4885 |
| US-20060281718-A1 | Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent | VRK1, VIPR1, AVPR1A | PTGS2 777/4885PTGS1 247/4885KDM4E 4666/4885 |
| US-20040214753-A1 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | OTC, AQP3, AQP1 | PTGS2 418/4885PTGS1 422/4885KDM4E 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.